Furthermore, the tumor microenvironment (TME) of EGFR-mutated NSCLC, characterized by a low tumor mutation burden (TMB), impaired T cell activity, and high levels of immunosuppressive cytokines, further complicates treatment outcomes [5,6]. The gene discussed is EGFR; the disease is neoplasm.